Nicholas Investment Partners’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Nicholas Investment Partners’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-19,188	Closed	-$84K	–	346
2015 Q1	$84K	Hold	19,188	–	–	0.01%	304
2014 Q4	$92K	Buy	+19,188	New	+$85.8K	0.01%	296
2014 Q2	–	Sell	-178,166	Closed	-$1.14M	–	326
2014 Q1	$1.14M	Sell	178,166 -23,027	-11%	-$208K	0.09%	269
2013 Q4	$1.92M	Buy	+201,193	New	+$1.57M	0.15%	217

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nicholas Investment Partners's TLOG Position: Q2 2015 in Review

Nicholas Investment Partners sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2015, closing a stake of 19,188 shares — an estimated $84K sold.

Nicholas Investment Partners first reported a position in TLOG in Q4 2013 and held it in 4 quarters. The position peaked at $1.92M in Q4 2013. 33 funds tracked by Wall St. Rank hold TLOG as of Q2 2015.

Nicholas Investment Partners reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2015 after selling out during the quarter.
Nicholas Investment Partners sold 19,188 TetraLogic Pharmaceuticals Corporation shares in Q2 2015, an estimated $84K.
Nicholas Investment Partners first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 4 quarters.
Nicholas Investment Partners's TetraLogic Pharmaceuticals Corporation position peaked at $1.92M in Q4 2013.
33 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2015.

Based on Nicholas Investment Partners's 13F filing for Q2 2015, filed 17 Aug 2015.